Vaccines have played an important role in significantly reducing the global burden of several serious infectious diseases. According to the World Health Organization (WHO), vaccination is one of the most successful and cost-effective public health interventions available. Behind every successful vaccine is a multi-functional, committed team of experts synchronizing the effort of people, processes and resources all working towards a shared goal: To help protect children and adults, across the globe from infectious diseases.
Inventprise is led by Founder and CEO, Subhash Kapre, PhD. His experience encompasses multiple senior executive vice president positions at Serum Institute of India Pvt. Ltd. (SIIPL), which measured by volume, is the world’s largest vaccine manufacturer. During his four-decade tenure at SIIPL, Subhash held multiple functional leadership positions in R&D, manufacturing, and vaccine discovery. He is a thought leader in rDNA technology, an internationally renowned expert in both bacterial and viral vaccines and has led certification of WHO- Prequalification (regulatory approval) for large scale manufacturing.He held board positions at Akorn, and Serum Institute of India, where he was board, executive director. Subhash has a history of driving multiple vaccines from discovery, into development and through licensure for infectious diseases, including MenAfriVac® and Pneumosil®, conjugate vaccines which together will represent over 500M aggregate doses delivered by 2022. Subhash holds over 70 patents and founded Inventprise in 2012 to continue his career long mission to provide vaccines for those most in need.
Yves Leurquin leads partnerships, capital formation and structural growth at Inventprise. Before joining Inventprise, Yves Leurquin was Global Head of Pricing and Tender Management for Takeda’s Vaccine Business Unit. He joined the newly created Takeda Vaccine Business Unit at its inception where he led the Asia Pacific Region and then the European Region. Yves also held corporate board positions, at Takeda Vaccine Internationals. Additionally, Yves prior experience included EVP International and Government Affairs at Johnson & Johnson (Crucell) with oversight of relations with the United Nations organizations as well as business responsibility for Latin America, Middle East, Africa and Asia where he led a -multi-functional team of marketing, sales and government affairs professionals generating two third of the group’s vaccine revenue. While at J&J Yves Leurquin organized the development and international launch of the first liquid Penta vaccine, winning supply contracts with UNICEF and PAHO and rapidly achieving a dominant market share. Prior to joining Johnson &Johnson, Yves was with the vaccine division of GlaxoSmithKline, holding progressively responsible positions over a 10-year tenure.
Pradip Ghate has over three decades of international experience working in developing and developed countries in Project and Operations management for Aseptic Sterile operations of biological and pharmaceutical products. He has direct experience managing multiple disciplines from Aseptic manufacturing, Quality Assurance, Quality Engineering and Systems Validation, Formulation, Fill, Finish & Packaging. His tenure at Serum Institute of India, Hemosol Inc, Cardinal Health, Catalent, and now Inventprise LLC consists of progressively increasing responsible titles ranging from Manufacturing head, project management to Chief Operating Officer. At Inventprise, Pradip is overseeing the day to day administrative and operational functions of our business. Pradip is a Certified Lean Six Sigma Black Belt and believes in Operational Excellence. His strategy planning and vision is the motive force behind operational objectives at Inventprise.
David Goesling is Inventprise Chief Financial Officer, he is a tenured financial executive with extensive startup and growth phase experience in both private and publicly traded corporations. Dave has been a key senior management leader in multiple leading-edge technology and life science companies and has completed a broad spectrum of equity, bank, and debt financings, raising billions of dollars in the aggregate to fuel growth. He has implemented complex financial systems and created process and infrastructure to enable scalable growth and cost efficiency. Dave has held senior financial management positions at development and commercial stage pharmaceutical and medical device companies for the past 15 years, including the development from pre-FDA approval to sale of RF Surgical Systems to Medtronic and a reverse merger transaction creating Armata Pharmaceuticals (ARMP) which is now in clinical trials evaluating engineered phage-based treatments.
At Inventprise, we believe that science is the solution to tomorrow’s greatest threats to human health. Meet our team of scientists from around the globe who strive to develop the best possible vaccines. As innovators of scientific solutions, Inventprise’s scientists face multiple challenges every day; yet, they remain driven by their passion and expertise. Their leadership is crucial in motivating our teams to overcome challenges and deliver the next generation of vaccines.
Dr. Florence Seal joined Inventprise in 2015 and is currently Head of the Immunology Laboratory in Bacterial Vaccine R&D.
Florence’s team is responsible for performing standardized multiplex immunoassays to evaluate stability and maintain quality control of conjugate vaccine products, as well as determine vaccine formulation immunogenicity in pre-clinical studies.
Florence obtained her PhD in Biochemistry at Hong Kong University in 2004. For postdoctoral research she worked on medical therapeutics at Neuroscience and Liver Transplant Department of Mayo Clinic Jacksonville from 2004–2013. Florence has published 18 research papers in peer reviewed journals including 9 as first author and has conducted studies in various medical fields such as Alzheimer’s, cancer, diabetes, and liver disease.
Dr. Gowri Chellappan’ s work focuses on the utilization of various chemistries for conjugation vaccine development against different disease targets. In addition, she leads the formulation development efforts employing different excipients, adjuvants and stabilizers for producing a stable and safe conjugate vaccine with optimal product quality attributes. Further, in addition to managing the overall technical aspects of various projects, Gowri handles project management activities for key Bill and Melinda Gates foundation funded projects where she coordinates with different groups on project deliverables and timelines and is an expert at devising risk assessment and mitigation strategies utilizing portfolio management tools.
Prior to joining Inventprise, Gowri held progressively responsible positions at GlaxoSmithKline Vaccines, Moderna Therapeutics and Merck Research Laboratories.
Dr. Fataneh Karandish is a motivated scientist with passion for innovation in science, technology and improving human health. She’s joined our team since 2018 and has contributed to projects such as proteins and polysaccharides purification, and polysaccharide-protein conjugated vaccines. Her experience in processes development and targeted drug delivery have been invaluable addition to our team.
Fataneh has received her PhD degree in Pharmaceutical science and recipient of the first prize of the Innovation Challenge award’17 at NDSU. She has published 7 research papers in peer reviewed journals with more than 160 citations.
Our functional leaders are critical to the success of Inventprise. At Inventprise, quality is at the center of everything we do. and we rely on our core team of functional leaders to ensure that we deliver on our key goals. Our functional leaders are industry veterans with wide ranging expertise and proven track records.
Ramesh Shanbhag has over 30 years of extensive experience in designing and implementing, facility and engineering projects in the pharmaceutical and biotech industry. Ramesh has successfully executed projects in 33 countries complying with USFDA, WHO and EU QUALITY & GMP regulations. Ramesh has experience in leading multidisciplinary multi-nationality project teams for successful execution of projects. Ramesh has a Professional Engineer (PE) certification from the U.S., and a Chartered Engineer(CEng) certification from the European Union.
Mark Silverberg has served as the head of Quality since 2019, he is responsible for quality systems, Quality Assurance / Quality Control, microbiological programming, validation, training and related support functions. Mark has 25+ years of senior management and C-Suite experience, dealing with both domestic and international business environments and regulated markets. Mark has held senior leadership positions in both large and small biotechnology companies, including global Quality Assurance: operations, R&D regulatory affairs, compliance, logistics and 3rd party alliances.